Stock Price
2.33
Daily Change
-0.04 -1.69%
Monthly
-20.48%
Yearly
76.52%
Q2 Forecast
2.28

Galectin Therapeutics reported 4.02 in Sales Revenues for its fiscal quarter ending in March of 2023.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Merck USD 16.4B 880M Dec/2025